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Abstract
We analyze one-year costs and savings of a telemedically supported case management program after kidney
transplantation from the perspective of the German Healthcare System. Recipients of living donor kidney
transplantation (N = 46) were randomly allocated to either (1) standard aftercare or (2) standard aftercare plus
additional telemedically supported case management. A range of cost figures of each patient’s medical service
utilization were calculated at month 3, 6 and 12 and analyzed using two-part regression models.
In comparison to standard aftercare, patients receiving telemedically supported case management are associated
with substantial lower costs related to unscheduled hospitalizations (mean difference: €3,417.46 per patient for the
entire one-year period, p = 0.003). Taking all cost figures into account, patients receiving standard aftercare are
associated, on average, with one-year medical service utilization costs of €10,449.28, while patients receiving
telemedically supported case management are associated with €5,504.21 of costs (mean difference: € 4,945.07 per
patient, p < 0.001). With estimated expenditures of €3,001.5 for telemedically supported case management of a
single patient, we determined a mean difference of €1,943.57, but this result is not statistically significant (p = 0.
128). Sensitivity analyses show that the program becomes cost-neutral at around ten participating patients, and was
beneficial starting at 15 patients. Routine implementation of telemedically supported case management in German
medium and high-volume transplant centers would result in annual cost savings of €791,033 for the German
healthcare system.
Patients with telemedically supported case management showed a lower utilization of medical services as well as
better medical outcomes. Therefore, such programs should be implemented in medium and high-volume
transplant centers.
Trial registration: DRKS00007634 (http://www.drks.de/DRKS00007634).
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Background
Successful solid organ transplantation can offer substan-
tial improvements to patient quality of life. However, the
recovery process after organ transplantations requires
continuous effort and therapy to ensure and maintain
satisfactory patient outcome and prevent graft loss [1].
Patient adherence to long-term medication is often
insufficient for a variety of reasons, and many potential
behavioral pitfalls have to be avoided [2–5].
Prevention of graft loss, beside its significance to indi-
vidual patients, also represents a concern to the health-
care system as a whole due to the high number of
patients on the German kidney waiting list and the per-
manent shortage of donor organs. In the literature there
are different propositions on how to reduce occurrence
of graft loss, however not all of them are equally effect-
ive in producing the desired results [6]. The continuing
progress of communication technology provides health-
care professionals an expanding set of tools to poten-
tially improve patient outcomes.
Our random controlled trial combines telemedically
supported case management and monitoring of pa-
tient’s vital data with video teleconferences between
the patient and the Transplantation Center Freiburg
[7]. The trial was registered with the German Clinical
Trials Register (www.DRKS.de) under the identifica-
tion number DKRS00007634.
The results of our random controlled trial show signifi-
cant improvements in medical and disease-specific out-
comes over the first year after transplantation as described
in detail in Schmid et al. [8].
But beyond this medical dimension, telemedically
supported case management also has an economic per-
spective. On the one hand costs of medical treatment
increased due to necessary investments into the new
telemedicine infrastructure and hiring and training of
specialized personnel. On the other hand cost savings
can be achieved due to prevention of medical emergen-
cies, elimination of unneeded doctor visits and specialist
consultations, and more appropriate therapy decisions.
With regard to the resulting net cost effects of telemedi-
cally supported intervention prior evidence is mixed and
sometimes flawed [9–12]. The benefits of telemedicine
in delivering effective care coordination have been con-
firmed in chronic disease conditions such as cardiac
insufficiency [13–15]. A new broad German study focus
on telemonitoring for COPD using routine data from a
major German sickness fund clearly demonstrates positive
effects on healthcare costs [16].
We advance the debate on routine implementation of
telemedicine in the health system using a case study
from the clearly delimited field of kidney transplanta-
tion’s aftercare. To best of our knowledge this is the first
evaluation of a telemedicine and case-management
intervention for transplantation patients with focus on
economic (budget) impact in the German healthcare
system, observing costs in the first year after transplant-
ation. Furthermore we demonstrate that even if it is
clear that a telemedicine intervention is dominant, i.e.
preferable both medically and economically to standard
care, the current reimbursement practice of German
sickness funds still makes it difficult to implement the
technique in a routine manner.
Methods
Data collection
A prospective, controlled, randomized and open project-
study was realized as follows [7]: In September 2011, 50
patients who were scheduled for a living-donor kidney
transplantation at the Transplantation Center Freiburg
between October 2011 and March 2012 were randomly
allocated to two groups receiving different aftercare pro-
grams during the first postoperative year.
The first group was offered standard aftercare in com-
bination with telemedically supported case management.
Daily, the patients completed a pre-defined medical
questionnaire about their physical condition presented
to them in their homes via an interactive web-based tele-
monitor. These data were monitored by medical staff
with a special qualification for work with patients after
kidney transplantation. If anomalous values occured, the
medical staff contacted the patient by phone or video
conference to discuss the following treatment process.
The control group was offered standard aftercare with-
out telemedically supported case management. Of the 50
randomized patients, two patients in each group
dropped out, resulting in 46 available valid datasets.
One-year costs of medical service utilization
At three points (3, 6 and 12 months after transplant-
ation), utilization of health care resources is recorded for
every patient. For outpatient care visits at general practi-
tioners (N = 194) and or medical specialists (N = 1829),
standardized unit costs from Bock et al [2014] [17] were
applied, representing costs from a societal perspective.
For scheduled (N = 39) and unscheduled (N = 68)
episodes of hospitalization, actual amounts of reim-
bursement were collected from the respective hospitals.
Ambulatory visits at the outpatient department were
priced according to the respective reimbursement (€270
per visit). All prices reflect 2015 values. Overall, six cost
figures (costs of general practitioner out-patient care
visits, costs of medical specialist out-patient care visits,
costs of scheduled in-hospital care, costs of unscheduled
in-hospital care, costs of ambulatory visits at the out-
patient department and total costs of care) were calcu-
lated for each observation period and patient.
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Costs of telemedically supported case management
Within the statutory health insurance in Germany,
telemedically supported case management is not an
element of standard care. A reimbursement by sick-
ness funds is possible by using individual case re-
quests, only. A hypothetical number of 20 patients
receiving telemedically supported case management
for a one year period is assumed to require an add-
itional 50% nurse position (€28,500) with a suitably
equipped work place (€500) and internal server
provision (€1,024). In addition, patient-variable costs
for a Touch-Screen-PC (€600) and software licenses
(€300 per year) are claimed. To these fixed (€30,024
for 20 hypothetical patients) and variable (€900 per
patient) costs of the one year telemedical support, an
extra 25% for infrastructure expenses was added.
Statistical analysis
Skewed data is a major issue in statistical models of
healthcare costs [18–20]. Beside the fact that the six cost
figures were positively skewed, most of them were equal
to zero during a considerable number of observation
periods because patients did not see a physician and/or
were not hospitalized in the respective time period. In
order to accommodate these characteristics of the data,
a two-part model approach was chosen for the regres-
sion analyses [21–24]. In two part models, a binary
choice model is estimated for the probability of observ-
ing a zero versus positive outcome. Then, conditional on
a positive outcome, an appropriate regression model is
estimated for the positive outcome [25]. For part one of
the applied models a logistic regression analysis was
chosen to predict whether or not patients would utilize
resources related to the respective costs figure. As
recommended in the literature [20, 21, 24, 26–28], a
generalized linear model (GLM) with the log link and
gamma distribution was chosen for the second part. In
order to first analyze the temporal development of the
cost estimates between the two treatment groups, an
interaction term between treatment group and observa-
tion period was used. The cluster option was used to
address the fact that multiple monthly cost estimates are
included in the dataset for the same patient. Then, the
respective resource uses were summarized over the one-
year period for each patient in order to analyze the
treatment-related cost differences across the entire one-
year period. Finally, a budget impact analysis [29] from
the healthcare perspective is performed by combining
the costs of a hypothetical number of 20 patients re-
ceiving telemedically supported case management with
the actual results of summarized resource uses in the
two groups. One-way sensitivity analyses are carried
out to assess the impact that changes in a certain par-
ameter will have on the analyses’ results. Marginal
means from all regression analyses are shown on the
raw scale (€ per observation period). All analyses were
performed using Stata 14 (Stata Corp., Texas. USA).
Results
Baseline characteristics
Table 1 provides an overview of baseline patient charac-
teristics. The medical results of the RCT this study is a
part of, including more detailed statistics, have been
published elsewhere [8].
One-year costs of medical service utilization
Table 2 provides estimates regarding the different cost
figures over the three observational periods. Between
month 0 and month 3 after transplantation, the number
of out-patient care visits is comparable between the two
groups. Between month 3 and month 6, however, the
group of patients with telemedically supported case
management required fewer medical specialist consulta-
tions, which is associated with average cost savings of €
293.54 per patient (p = 0.036) for this period. Between
month 6 and month 12 after transplantation, these cost
savings increase to € 419.12 (p = 0.089). Over the entire
one-year period, patients with telemedically supported
case management substantially less frequently visited
medical specialists, resulting in total cost savings of €
761.37 per patient (p = 0.048). As far as general practi-
tioner visits are concerned, on the other hand, the costs
are relatively identical between both groups (p = 0.879).
As a result of early diagnoses and short delay be-
tween the first onset of symptoms and initiation of
treatment, telemedically supported case management
is associated with substantial cost savings related to
unscheduled hospitalizations. The associated cost
savings are highest between month 3 and month 6
after transplantation and add up to savings of €
3417.46 (p = 0.003) for the entire one-year period.
The costs of scheduled in-hospital care, in contrast,
are less affected by telemedically supported case
management (cost savings of € 964.31 over the entire
Table 1 Patient baseline characteristics after kidney
transplantation (timepoint 0)
Characteristics Standard Telemedical
Median age in years (range) 51 (19–66) 46 (18–59)
Male sex 47,8% 60,9%
ABO-incompatible living kidney graft 26.1% 30.4%
HLA-Mismatches ≤ 4 43.5% 47.8%
First graft 82.6% 82.6%
Postoperative complications 52.2% 47.8%
Median graft GFR in ml 57.99 53.99
(range) (13.60–82.92) (38,48–81,95)
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one-year period, p = 0.073). On the other hand, pa-
tients with telemedically supported case management
more often applied for ambulatory visits at the uni-
versity outpatient department, resulting in additional
costs of € 117.39 (p = 0.035) for the entire one-year
period. Overall, telemedically supported case manage-
ment is clearly associated with cost savings due to
less frequent and/or less intense medical service
utilization during the one-year period (see Fig. 1).
These savings are highest between month 3 and
month 6 after transplantation (€ 2166.36, p < 0.001)
and add up to total savings of € 4945.07 (p < 0.001)
for the entire one-year period. Overall, patients in
the standard aftercare group are associated, on aver-
age, with €10,449.28 of on-year medical service
utilization costs while patients with telemedically
supported case management are associated with
€5,504.21 of on-year medical service utilization costs.
Table 2 Comparison of cost across the six cost figures
Month 0‐3 Month 3‐6 Month 6‐12 Total cost p‐value (total costs)
Costs of primary care physician visits:
Standard €13.39 €20.44 €35.94 €69.77
Telemedical €11.28 €21.85 €33.83 €66.95
Difference €2.11 -€1.41 €2.11 €2.82 0.879
Costs of specialist consultant visits:
Standard €650.31 €746.58 €1,053.31 €2,450.20
Telemedical €601.60 €453.04 €634.20 €1,688.83
Difference €48.72 €293.54 €419.12 €761.37 0.048
Costs of unscheduled in‐hospital care:
Standard €2,376.24 €1,813.49 €1,245.33 €5,435.06
Telemedical €1,463.60 €190.78 €363.23 €2,017.60
Difference €912.64 €1,622.72 €882.10 €3,417.46 0.003
Costs of scheduled in‐hospital care:
Standard €885.77 €338.14 €640.82 €1,920.36
Telemedical €843.79 €39.66 €72.60 €956.05
Difference €41.98 €298.47 €568.22 €964.31 0.073
Costs of amulatory visists at the university outpatient department:
Standard €246.52 €199.57 €211.30 €657.39
Telemedical €258.26 €246.52 €270.00 €774.78
Difference -€11.74 -€46.96 -€58.70 -€117.39
Total costs of care:
Standard €4,172.23 €3,118.21 €3,158.84 €10,449.28
Telemedical €3,178.52 €951.84 €1,373.85 €5,504.21
Difference €993.71 €2,166.36 €1,784.99 €4,945.07
Fig. 1 Total costs of care. a standard aftercare and b telemedically supported case management
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Budget impact analysis1 of telemedically supported case
management
The main objective of our study is to calculate the
budget impact of the telemedically supported case man-
agement from the healthcare perspective. As a first step
our analysis combines the costs of a hypothetical num-
ber of 20 patients receiving telemedically supported case
management with the actual results of summarized
resource uses in the two groups. As a result, costs of
telemedically supported case management are estimated
at €3,001.5 for a single patient. Although being hypo-
thetical, this cost figure equals the amount of reimburse-
ment from the different sickness funds using individual
case requests. After combining this reimbursement
(€3,001.5) with the costs of medical service utilization
(€5,504.21, see above), the one-year costs in the teleme-
dically supported case management group add up to
€8,505.71. In comparison to the costs of medical service
utilization in the standard aftercare group (€10,449.28,
see above), telemedically supported case management
may still be associated with lower costs (mean differ-
ence: €1,943.57), but this result is not statistically
significant (p = 0.128).
As a first sensitivity analysis, we calculate the net
savings of our telemedically supported case management
program depending on the number of patients partici-
pating. Due to the effect of fixed cost degression the
program becomes cost-neutral at around ten participat-
ing patients, and was beneficial at 15 patients (see Fig. 2).
After an initial rapid increase, the increase of savings
begins to level off, increasing from €67 at a program
size of ten patients to €1318 at 15 patients, but only
from €2318 to €2569 from 25 to 30 patients. The re-
sults are projected to become statistically significant
(p < 0.05) at a program size of 30 patients. Please note
that the results for more than 20 patients imply the
assumption that an additional 50% nurse position may
can provide telemedically supported case management
to more than 20 patients.
As a second sensitivity analysis, we kept the share of
personnel expenses (an additional 50% nurse position
for 20 patients) flexible. We assumed a 2.5% nurse
position necessary for every additional patient with tele-
medically supported case management (which is equal
to €1,781.25). As shown in Fig. 2, the program now
becomes beneficial even from a very low number of
patients. Please note that these results imply the as-
sumption that the nurse position may be easily increased
and decreased relative to the number of patients with
telemedically supported case management. All results of
the sensitivity analyses are shown in Table 3.
Finally we transfer our results to the German healthcare
system. We recommend that the program should be im-
plemented in bigger transplant centers like Freiburg, with
more than 30 living donor kidney transplantations a year.
The program is highly feasible and, if implemented in this
way, would result in significant savings of upwards of
€3,000 per patient and year of telemedically supported
case management. According to EuroTransplant, a total
of 645 living kidney transplantations were conducted in
38 German transplant centers in 2015 [30]. Of these, 12
centers conducted more than 20 transplantations (n ~ 407
in total). According to our results, routine implementation
of telemedically supported case management in these 12
centers would result in annual savings of €791,033 accord-
ing to the procedure numbers of 2015 and the results of
our base case scenario.
Discussion
Overall, the results of our study show that telemedically
supported case management is associated with a sub-
stantially lower frequency of medical service utilization.
As a result, one-year costs of care for these patients
(€5,504.21) are roughly half the costs in the standard
aftercare group (€10,449.28). Analysis of the different
cost categories shows that the major drivers of these
differences are episodes of unscheduled in-hospital care.
This confirms the main rationale behind the study: An
Fig. 2 Cost savings per patient. a …keeping the fixed costs at a constant level and b …keeping the share of personnel expenses flexible
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early diagnosis and short delay between the first onset of
symptoms and initiation of treatment correlates with
substantially lower medical service utilization. Our tele-
medicine intervention has shown to be effective at
improving several important outcome measures of living
donor kidney transplantation. The intervention has
shown promise for better medical and disease-specific
outcomes as well as saving costs – a win-win situation.
From the healthcare perspective, an implementation
of the program in the 12 biggest transplant centers in
Germany would result in annual net savings of €791,033
per year. However, the current reimbursement practice
requires requests to be made for each case separately to
each of the 117 German statutory health insurances. This
may be seen as the main hurdle for implementing
telemedically supported case management in other
centers for the following reasons: Firstly, the high
number of requests goes hand in hand with high ne-
gotiation and administrative costs. Secondly, from the
point of view of the supplier of telemedicine aftercare
infrastructure (in this case the transplantation center)
the reimbursement and therefore the utilization of the
investment is a priori uncertain. Thus, we propose to
reimburse telemedically supported case management
by sickness funds in a routine manner. Political action
is needed in order to unlock these potential patient-
and societal-level benefits.
Our study avoids several of the problems that are
otherwise common in studies of the cost-efficacy of tele-
medicine [9, 10]. However, please note that the results of
the present study are still subject to a number of limita-
tions. First of all, 23 patients in each group is a very
limited number of patients given the wide variation in
cost measures. As a result, measures of significance in
many cases do not reach the usual level of significance
(p < 0.05) and results should be interpreted with the
according caution. Also, the patient population was not
large enough to properly control for socioeconomic
background. For example, elderly patients might still be
less comfortable with using telemedical devices, which
could result in this or other patient populations receiv-
ing better results from traditional aftercare programs.
On the other hand this means that taking such factors
into account in the patient selection process, or making
adjustments to our telemedical equipment and tech-
niques to improve accessibility for any patients currently
struggling to make best use of the equipment, might fur-
ther improve the already significant impact of telemedi-
cal support on patient outcomes and costs we measured.
Secondly, collection of patient-level cost data during
follow-up is a resource intensive exercise. In order to
simplify this process, we decided to apply standardized
unit cost for visits at primary care physicians, specialist or
ambulatory visits at the university outpatient department
Table 3 Budget impact analysis
Hypothetical n Standard Telemedical Difference p-value
Sensitivity analysis 1: 5‐30 patients, fixed costs at a constant level (in € and per patient)
Base case 5 patients € 10449.28 € 14135.21 ‐€3685.93 0.004
10 patients € 10449.28 € 10382.21 € 67.07 0.958
15 patients € 10449.28 € 9131.21 € 1318.07 0.301
20 patients € 10449.28 € 8505.71 € 1943.57 0.128
23 patients € 10449.28 € 8260.95 € 2188.33 0.086
25 patients € 10449.28 € 8130.41 € 2318.87 0.069
30 patients € 10449.28 € 7880.21 € 2569.07 0.044
Sensitivity analysis 2: 5‐50 patients, keeping personal cost flexible (in € and per patient)
Base case 5 patients € 10449.28 € 8791.46 € 1657.82 0.194
10 patients € 10449.28 € 8600.96 € 1848.32 0.147
15 patients € 10449.28 € 8537.46 € 1911.82 0.134
20 patients € 10449.28 € 8505.71 € 1943.57 0.128
23 patients € 10449.28 € 8493.28 € 1955.99 0.125
25 patients € 10449.28 € 8486.66 € 1962.62 0.124
30 patients € 10449.28 € 8473.96 € 1975.32 0.121
35 patients € 10449.28 € 8464.89 € 1984.39 0.12
40 patients € 10449.28 € 8458.08 € 1991.20 0.118
45 patients € 10449.28 € 8452.79 € 1996.49 0.117
50 patients € 10449.28 € 8448.56 € 2000.72 0.117
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[17]. Presumably, this simplification might underestimate
the true ambulatory expenditures as ambulatory care of
transplant patients is exceptionally resource intensive. In
addition, this simplification completely ignores medical
treatment expenditures. Immunosuppressive regimes in
renal transplant patients are costly, but adherence with
medication may be considered of major importance for
post-procedural outcomes [31]. Probably, adherence with
medication is also improved by telemedically supported
case management due to the fact that unnecessary
changes in the drug therapy can be avoided. Recent regu-
latory changes towards an exclusion of immunosuppres-
sive regimes from aut idem regulations in Germany
underline the necessity of medication adherence among
transplant patients [32, 33].
Conclusions
Our random controlled trial, covering about 7% of all liv-
ing kidney transplantations conducted in Germany over
the trial period, shows that the introduction of telemedi-
cally supported case management results not only in
significant improvements in medical and disease-specific
outcomes, but also a considerable potential for cost
savings within the first year after transplantation, mainly
by avoiding episodes of unscheduled in-hospital care.
Due to the effect of fixed cost degression we rec-
ommend that the program should be implemented in
medium and high volume transplant centers. This
would result in annual savings of almost €800,000 for
the German healthcare system for living kidney trans-
plantations alone.
From a broader perspective the major hurdle still stand-
ing in the way of widespread introduction of the telemedi-
cine aftercare technique at the interface between the
outpatient and inpatient sectors is the current reimburse-
ment practice, in which requests have to be made for each
case separately to each of the German statutory health
insurances, representing a significant administrative hur-
dle. Hence, provision would have to be made for telemedi-
cally supported case management to be reimbursable by
sickness funds in a routine manner.
Endnote
1Additional to our cost perspective the results also can
be interpreted as net benefit to the patients, since their
quality of life and health is improved by the earlier diag-
nosis and short delay between the first onset of symp-
toms and initiation of treatment resulting from the
telemedical supported case management program.
Abbreviation
GLM: Generalized linear model
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